Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 15:16:2447-2458.
doi: 10.2147/RMHP.S436750. eCollection 2023.

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

Chongchong Zhou #  1   2 , Jingxuan Wei #  1 , Kai Xu  1 , Yingtao Lin  3   4 , Lingli Zhang  1 , Xin Li  1   4   5
Affiliations

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

Chongchong Zhou et al. Risk Manag Healthc Policy. .

Abstract

Background: Tislelizumab plus chemotherapy improved overall survival compared to chemotherapy alone, while maintaining an acceptable level of safety. But it's still unclear which strategy is the most cost-effective. The objective of the study was to compare the cost-effectiveness of tislelizumab plus chemotherapy as first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) versus chemotherapy alone.

Methods: A partitioned survival model with three states was constructed based on the RATIONALE-306 trial. The model's time horizon was ten years, and its cycle was three weeks. Only direct medical costs were considered from the healthcare perspective in China. Calculations were performed on total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way sensitivity and probabilistic sensitivity analysis (PSA) were performed to determine the uncertainty regarding model parameters.

Results: Tislelizumab plus chemotherapy provided 1.35 QALYs for $26,450.77, while chemotherapy alone provided 0.89 QALY for $16,687.15. Compared to chemotherapy alone, tislelizumab had an ICER of $21,062.09/QALY. At the threshold of three times the Chinese GDP per capita ($38,253/QALY), the PSA indicated that tislelizumab had a 96.4% likelihood of being designated cost-effective. At the threshold of 1.5 times the Chinese GDP per capita ($19,126.5/QALY), the PSA indicated that tislelizumab had a probability of 48.7% of being designated cost-effective.

Conclusion: Tislelizumab plus chemotherapy as the first treatment for patients with advanced or metastatic ESCC may be a cost-effective option compared to chemotherapy alone at 3 times Chinese GDP per capita.

Keywords: cost-effectiveness; esophageal squamous cell carcinoma; partitioned survival model; tislelizumab.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The model structure of the partitioned survival model.
Figure 2
Figure 2
Tornado diagram of one-way sensitivity analyses of tislelizumab plus chemotherapy versus placebo plus chemotherapy in order of magnitude of the association.
Figure 3
Figure 3
ICER scatter plot of tislelizumab plus chemotherapy vs placebo plus chemotherapy.
Figure 4
Figure 4
Cost-effectiveness acceptability curves for tislelizumab plus chemotherapy vs placebo plus chemotherapy.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel R, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Li L, Jiang D, Zhang Q, et al. Integrative proteogenomic characterization of early esophageal cancer. Nat Commun. 2023;14(1):1666. doi:10.1038/s41467-023-37440-w - DOI - PMC - PubMed
    1. Li B, Liu Y, Peng J, Sun C, Rang W. Trends of esophageal cancer incidence and mortality and its influencing factors in China. Risk Manag Healthc Policy. 2021;14:4809–4821. doi:10.2147/rmhp.S312790 - DOI - PMC - PubMed
    1. Liu Z, Li Z, Zhang Y, et al. Interpretation of the 2020 global cancer statistical report. Elec J Elec Compr Canc Therapy. 2021;7(02):1–14.
    1. Li Y, Xu J, Gu Y, Sun X, Dong H, Chen C. The disease and economic burdens of esophageal cancer in China from 2013 to 2030: dynamic cohort modeling study. JMIR Public Health Surveillance. 2022;8(3):e33191. doi:10.2196/33191 - DOI - PMC - PubMed